NEW YORK, Feb 8 – Hyseq’s dwindling cash reserves notwithstanding, many investors and analysts expressed confidence that CEO George Rathmann would recruit the necessary financing to keep the company afloat.

The Sunnyvale, Calif.-based biopharmaceutical company said this morning that its reserves had dropped to just $2.7 million at the end of 2000, down from $30 million a year previously, and that Rathmann would extend a $20 million line of credit to help finance the company’s drug development efforts.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.